Severe urticaria

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The article presents the concept of the severity of chronic idiopathic (spontaneous) urticaria, evaluation, disease control, masks of chronic urticaria, risks and treatment.

Full Text

Restricted Access

About the authors

I V Danilycheva

Institute of Immunology

A E Shulzhenko

Institute of Immunology


  1. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/ EDF/WAO Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy. 2014, v. 69, p. 868-887.
  2. Paul E., Greilich K.D., Dominante G. Epidemiology of urticaria. Monogr. Allergy. 1987, v. 21, p. 87-115.
  3. Paul A. Greenberger. Chronic urticaria: new management options. World Allergy Organization Journal. 2014, v. 7, p. 31.
  4. Sabroe R.A., Greaves M.W. The pathogenesis of chronic idiopathic urticaria. Arch. Dermatol. 1997, v. 133, p. 1003-1008.
  5. Kozel M.M., Sabroe R.A. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004, v. 64, p. 2515-2536.
  6. Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011, v. 66, p. 317-330.
  7. Maurer M., Church M.K., Goncalo M. et al. Management and treatment of chronic urticaria (CU). JEADV. 2015, v. 29, p. 16-32.
  8. Bousquet J., Anto J.M., Demoly P. et al. Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int. Arch. Allergy Immunol. 2012, v. 158, p. 216-231.
  9. Федеральный закон от 21.11.2011 № 323-ФЗ «Об основах охраны здоровья граждан в Российской Федерации» СЗ РФ. 2011, № 48, ст. 6724 (п. 20 ст. 2).
  10. Mathias S.D., Dreskin S.C., Kaplan A. et al. Development of a daily diary for patients with chronic idiopathic urticaria. Ann. Allergy Asthma Immunol. 2010, v. 105, p. 142-148.
  11. Mlynek A., Zalewska-Janowska A., Martus P. et al. How to assess disease activity in patients with chronic urticaria? Allergy. 2008, v. 63, p. 777-780.
  12. Baiardini I., Braido F., Brandi S., Canonica G.W. Allergic diseases and their impact on quality of life. Ann. Allergy Asthma Immunol. 2006, v. 97, p. 419-428.
  13. Zuberbier T., Asero R., Bindslev-Jensen C. et al. EAACI/ GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy. 2009, v. 64, p. 1417-1426.
  14. Gimenez-Arnau A.M., Grattan C., Zuberbier T., Toubi E. An individualized diagnostic approach based on guidelines for chronic urticaria (CU). JEADV. 2015, v. 29, p. 3-11.
  15. Stull D., McBride D., Georgiou P. et al. Measuring patient severity in chronic spontaneous/idiopathic urticaria (CSU/ CIU) as categorical health states: efficient and informative? Allergy. 2014, v. 69, p. 317 (Abstract 826).
  16. Magerl M., Borzova E., Gimenez-Arnau A. et al. The definition and diagnostic testing of physical and cholinergic urticarias--EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy. 2009, v. 64, p. 1715-1721.
  17. Weller K., Groffik A., Church M.K. et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J. Allergy Clin. Immunol. 2014, v. 133, p. 1365-1372.
  18. Valent P., Arock M., Bischoff S.C. et al. The European Competence Network on Mastocytosis (ECNM). Wien Klin. Wochenschr. 2004, v. 30, p. 647-651.
  19. Grotz W., Baba H.A., Becker J.U., Baumgärtel M.W. Hypocomplementemic Urticarial Vasculitis Syndrome, Dtsch. Arztebl. Int. 2009, v. 106, p. 756-763.
  20. Kulthanan K., Cheepsomsong M., Jiamton S. Etiokogy and course of urticarial vasculitis. Asian Pacific Journal Of Allergy And Immunology. 2009, v. 27, p. 95-102.
  21. Carlson J.A, Cavaliere L.F., Grant-Kels J.M. Cutaneous vasculitis: diagnosis and management. Clin. Dermatol. 2006, v. 24, p. 414-442.
  22. Krause K., Grattan C.E., Bindslev-Jensen C. et al. How not to miss autoinflammatory diseases masquerading as urticaria. Allergy. 2012, v. 67, p. 1465-1474.
  23. Siebenhaar F., Akin C., Bindslev-Jensen C., Marcus Maurer, Sigurd Broesby-Olsen. Treatment Strategies in Mastocytosis. Immunology&Allergy Clinic. 2014, v. 34, p. 433-447.
  24. Борисова Т.В., Сокуренко С.И. Ангиоотеки: классификация, диагностика, подходы к терапии. Клиническая практика. 2014, № 3, c. 71-83.
  25. Dreskin S.C., Andrews K.Y. The thyroid and urticaria. Curr. Opin. Allergy Clin. Immunol. 2005, v. 5, p. 408-412.
  26. Данилычева И.В., Ильина Н.И., Лусс Л.В. и соавт. Федеральные клинические рекомендации по диагностике и лечению крапивницы. Рос. Аллергол. Журн. 2016, № 1, с. 38-46.
  27. Staevska M., Popov T., Kralimarkova T. et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010, v. 125, p. 676-682.
  28. Kaplan A.P., Gimenez-Arnau A.M., Saini S.S. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017, v. 72, p. 519-533.
  29. Bousquet J., Rabe K., Humbert M. et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med. 2007, v. 101, p. 1483-1492.
  30. Holgate S., Buhl R., Bousquet J. et al. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir. Med. 2009, v. 103, p. 1098-1113.
  31. Kaplan A.P., Gimenez-Arnau A.M., Saini S.S. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017, v. 72, p. 519-533.
  32. Metz M., Ohanyan T., Church M.K. et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
  33. Presta L.G., Lahr S.J., Shields R.L. et al. Humanization of an antibody directed against IgE. J. Immunol. 1993, v. 151, p. 2623-2632.
  34. Shields R.L., Whether W.R., Zioncheck K. et al. Inhibition of allergic reactions with antibodies to IgE. Int. Arch. Allergy Immunol. 1995, v. 107, p. 308-312.
  35. Maurer M., Church M.K., Goncalo M. et al. Management and treatment of chronic urticaria (CU). JEADV. 2015, v. 29, p. 16-32.
  36. Maurer M., Church M.K., Marsland A.M. Questions and answers in chronic urticaria: where do we stand and where do we go? JEADV. 2016, v. 30, p. 7-15.
  37. Gimenez-Arnau A.M., Toubi E., Marsland A.M., Maurer M. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. JEADV. 2016, v. 30, p. 25-32.
  38. Maurer M., Altrichter S., Bieber T. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol. 2011, v. 128, p. 202-209.
  39. Kanani A., Schellenberg R., Warrington R. Allergy, Asthma&-Clinical Immunology. 2011, v. 7, p. 1-9.

Copyright © Pharmarus Print Media, 2017

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies